Project Grant R01HL187823
Award Date 8/5/26
Completion Date 5/31/30
Dollars Obligated $591K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $1,601,981 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate protein aggregation mechanisms in hematopoietic stem cells and their relationship to stem cell aging. The research examines how hematopoietic stem cells traffic misfolded proteins to aggresomes—cytosolic inclusion bodies that are substrates for selective autophagy—and tests the hypothesis...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute awarded Duke University $814,943 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop non-viral gene therapy approaches for cardiac regeneration following myocardial injury. Duke University will develop cardiac-targeted lipid nanoparticles for in vivo transfection of cardiomyocytes and adapt a cell-state sensing platform (CELLREADR) to deliver therapeutic transgenes with cell-type precision to injured...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Sanford Burnham Prebys Medical Discovery Institute $1,603,648 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a single-construct gene therapy for enhanced cardiac repair. The funded research aims to overcome barriers to cardiac reprogramming by creating a gene therapy that simultaneously induces overexpression of cardiac transcription factors MEF2C, GATA4, and TBX5 (MGT)...
- The National Heart, Lung, and Blood Institute awarded Yale University $444,015 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to develop human chimeric antigen receptor natural killer (CAR-NK) cells targeting cardiac fibrosis. The project, funded as an R21 Project Grant, will engineer universal CAR-NK cells derived from hypoimmunogenic human induced pluripotent stem cells with inactivated HLA class I/II and CD47 overexpression to enable off-the-shelf,...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $768,830 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune-fibroblast crosstalk in genetic dilated cardiomyopathy. The research integrates patient-specific induced pluripotent stem cells (iPSCs), three-dimensional cardiac organoids embedded in engineered disease-specific niches, CRISPR-based high-throughput screening, single-cell RNA sequencing,...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $779,600 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the developmental mechanisms that direct cardiac cell diversification and left ventricle morphogenesis. The research employs single-cell transcriptomic analyses and lineage tracing in mouse embryos to define the gene regulatory networks controlling how diverse cardiac cell types emerge from...
- The National Heart, Lung, and Blood Institute awarded the University of Cincinnati Sponsored Research Services Division $1.57 million on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on targeted rewiring of fibrosis drivers to enhance cardiac reprogramming following myocardial infarction. The research addresses excessive cardiac fibrosis resulting from the heart's repair response, which can lead to adverse remodeling and heart failure. The...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.379 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardioprotective mechanisms of Y RNA signaling in macrophages as a potential therapeutic approach to myocardial infarction. The research dissects how a small non-coding RNA called YREX3—secreted by therapeutically-enhanced cardiac stromal cells—signals macrophages to enhance their capacity for...